Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Angioblast Systems, Inc., a biotechnology company, engages in the development and commercialization of therapeutic products for the treatment of cardiovascular diseases. It provides adult stem cells, protein therapeutics, gene silencing, small molecule peptides and antibodies, cytokines and antigen-receptor inhibitors, and DNAzymes, as well as MPC products for heart failure, heart attacks, peripheral artery diseases, and wound ulcers. The company has a strategic alliance with Mesoblast Limited. Angioblast Systems, Inc. was founded in 2001 and is headquartered in New York, New York.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health. The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.

The Schepens Eye Research Institute, Inc. operates as an eye research institute. It offers treatment for macular degeneration, diabetic retinopathy, glaucoma, other types of retinal and optic nerve degenerations and damage, dry eye and eye tissue transplants. The company was founded by Charles L. Schepens in 1950 and is headquartered in Boston, MA.

Miltenyi Biotec, Inc. provides equipment and related services for biomedical research. The company was founded on April 2, 1992 and is headquartered in Auburn, CA.

Inguran LLC provides genetic improvement services for the livestock industry. It offers sexed semen to the dairy and other livestock industries. The firm?s services include semen collection, in vitro fertilization, and embryo collection and transfer. The company was founded in 2004 and is headquartered in Navasota, TX.

On-chip Biotechnologies Co., Ltd. develops and manufactures flowcytometer and cell sorters. Its solutions adopt the micro-fluid chip to detect and separate cells from a small amount of sample. The firm��s products include On-chip Sort, a micro-fluid chip cell sorter; On-chip Flow, a micro-fluidic chip FCM; reagents to prevent cell blockages in the micro-flow channels and accessories for On-chip Flow and On-chip Sort. The company was founded on April 1, 2005 and is headquartered in Koganei-shi, Japan.

NanoCellect Biomedical, Inc. develops flow cytometry and cell sorting technology solutions for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine. Its products include wolf cell sorter and N1 single cell dispenser. The company was founded by Nate Heintzman and Yuhwa Lo in 2009 and is headquartered in San Diego, CA.

TL Genomics is a developer of a prenatal diagnosis technology created to isolate fetal nucleated red blood cells in maternal blood.The company isolates fetal cells in maternal blood using a uniquely developed technology and examines the genome of the fetal cells, enabling noninvasive and definitive diagnosis of fetal chromosomal disease early in pregnancy.

Part of AstraZeneca PLC, Cambridge Antibody Technology Group Ltd. is a British company located in Cambridge that functions as an holding company whose subsidiaries researches, develops and exploits molecular engineering products. It was founded in 1996.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.

Shenzhen Cetro Biomedical Technology Co., Ltd., established on 2012-03-19, Business scope includes general business items:Research and development of medical technology products;Domestic Trade,Import and export business(law,Except for items prohibited by administrative regulations,law,Projects restricted by administrative regulations must be licensed before they can be operated).,The licensing program is:

Changchun Changguang Chenying Bioscience Instrument Co., Ltd., established on 2017-09-01, The business scope includes biological science instruments,Optical Instruments,Optical element,Optoelectronic components,Instrument R&D,Production,Sales,Biotechnology promotion,Information Technology Consulting,business management,Conference Services,Display and Exhibition Services,Import and export trade management;Technology development in the field of biomedical technology,technology transfer,Technical Consulting and Technical Services,Medical device management,computer software development,Sales,Technical consultation and service,technology transfer,Computer Information Technology Consulting,Production of chemical reagents(Excluding flammable and explosive dangerous goods),biological reagent,Consumables,biological test,Metal Products Processing,Machine made,Fabrication of Metal Structures,Forming of non-metallic structures,Processing machinery manufacturing,Metal Products Leasing Business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Mitsui E&S Shipbuilding Co., Ltd. engages in the design, manufacture, construction, and engineering ships and air cushion boats. The company was founded in 1917 and is headquartered in Tokyo, Japan.

Viridos develops and commercializes genomic-driven solutions to address global energy and environmental challenges. The company engages in synthesizing and programming DNA in developing and utilizing the technologies in synthetic genomics. It designs and develops microbes for industrial processes and environmental applications. The company also develops microbial cultivation technologies and monitoring approaches that reveal novel microorganisms, suites of new genes, and fermentation platforms for the metabolic engineering of microbes for commercial Bioenergy applications. In addition, it involves in designing advanced biofuels with properties compared to ethanol and biodiesel; harnessing photosynthetic organisms to produce value-added products directly from sunlight and carbon dioxide; developing new biological solutions to enhance production and/or recovery rates of subsurface hydrocarbons; and developing high-yielding, disease resistant, and economic feedstocks. The company's solutions help in improving the production of energy, chemicals, and pharmaceuticals, as well as enabling carbon sequestration and environmental remediation.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

XY LLC develops sex selection technologies for non-human mammals. The company is headquartered in Navasota, TX.